Profile | About Lindis Biotech
We combine scientific & pharmaceutical experience. We endeavour in safe and efficacious biomedical products.
Lindis Biotech is a clinical stage bio-pharmaceutical company, committed to develop innovative T- cell engaging trifunctional bispecific antibodies, Triomab® to turn malignant cancers into manageable and possibly curable diseases.
The lead Triomab®, Catumaxomab (Removab®), was the first approved T- cell engaging multi-specific antibody worldwide and validated this promising new approach among immuno-oncology therapies.
Since it’s foundation, Lindis Biotech acquired selected assets and continued as a lean company operating by using extensive outsourcing and having a pipeline of three advanced product candidates.
The people behind Lindis Biotech.
Dr. Horst Lindhofer
Horst Lindhofer, Ph.D., is the founder and CEO of LINDIS Biotech GmbH and TRION Research GmbH. He was also the co-founder and CEO of TRION Pharma GmbH.
Horst Lindhofer is an expert and pioneer in the field of antibody technology and cancer immunotherapy. He has developed and published innovative approaches in the field of multi-specific antibodies, not only to elucidate immunological mechanisms how to control cancer but also to improve and solve production problems.
He proposed the new mode-of-action of T-cell engaging trifunctional antibodies in cancer immunotherapy and named them Triomabs®.
The design of the Triomab® antibodies combine for the first time the direct, tumor-cell killing and an antitumor vaccine approach. For this achievement, he received in 2002 the AIO Award of the German Cancer Association, Berlin, for great contribution to tumor-biological research and development together with his colleague Peter Ruf.
In 2009, catumaxomab (brand name REMOVAB®), the lead compound of the Triomab® antibody platform series, was the first multi-specific antibody worldwide to receive EU approval for the treatment of malignant ascites induced by EpCAM positive carcinomas. This outstanding achievement created a new perspective in the immuno-oncology field of cancer treatment. For this milestone, Dr Lindhofer’s company Trion Pharma received the prestigious Step Award for “Product/Technology” in 2009 and the medicinal product REMOVAB® was priced by the “Galenus von Pergamon” Award in the category “Specialist Care” in 2010.
Horst Lindhofer is the inventor or coinventor of more than 20 patents, many of which are granted globally. He is the author or coauthor of more than 50 scientific publications and or book chapters.
Dr. rer. nat. Peter Ruf (PhD)
Dr Ruf joined Lindis Biotech in June 2017 as Head of Project Management and since January 2020 he has served as its Chief Operating Officer. He has 20 years of experience in tumor immunotherapy research, industrial processes and team leading.
Prior to joining Lindis Biotech, Dr Ruf headed the department of Antibody Development at Trion Research GmbH in Munich, Germany.
He was responsible for the new generation of trifunctional antibodies and their transfer from laboratory to industrial production scale. He supervised multiple therapeutic antibody studies on primary and secondary pharmacodynamics and pharmacokinetics that contributed to the European market approval of Removab®, the first multi-specific, T- cell redirecting antibody for cancer therapy.
Moreover, he coordinated and assumed scientific responsibility for several public funded projects and supported the application of many patents.
Dr Ruf received a Ph.D. in Biology from the Ludwig Maximilians University in Munich.
He is the author or co-author of more than 20 original articles in peer-reviewed scientific journals and syndicated books on trifunctional monoclonal antibodies and immunotherapy.
In 2002, he received the AIO Scientific Award from the German Cancer Society for his contributions in the field of tumor biological research.
Image Credits: Aerial Mike | 143712560 | Adobe Stock